Preventive therapies for migraine headache

P and T

Volumn 29, Issue 12, 2004, Pages 784-791

  Banks, James W ^a,b  

^a Family Practice Medical Education   (United States)

^b CARILION CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CYPROHEPTADINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOT ALKALOID; FEMOXETINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; LAMOTRIGINE; LITHIUM; METHYSERGIDE; METHYSERGIDE MALEATE; NEUROMODULIN; NIFEDIPINE; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROPRANOLOL; PROPRANOLOL DERIVATIVE; RIBOFLAVIN; SEROTONIN UPTAKE INHIBITOR; TIMOLOL; TIMOLOL MALEATE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

ABDOMINAL PAIN; ALTERNATIVE MEDICINE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HUMAN; LETHARGY; MENTAL DISEASE; MIGRAINE; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; SOMNOLENCE; SUPPLEMENTATION; TACHYCARDIA; TASTE DISORDER; WEIGHT GAIN; XEROSTOMIA;

EID: 11344254846     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Centers for Disease Control and Prevention (CDC). Statistics: Prevalence of diabetes in the U.S. Available at: www.cdc.gov/diabetes/statistics/prev/ national/fig1.htm.
2. Centers for Disease Control and Prevention (CDC). Asthma prevalence, health care use, and mortality, 2000-2001. Available at: www.cdc.gov/nchs/ products/pibs/pubd/hestats/asthma/asthma.htm.
3. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646-657.
4. World Health Organization (WHO). World Heath Report 2001. Mental Health: New Understanding, New Hope. Geneva, Switzerland; 2001.
5. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Haedache 2001;41:638-645.
6. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: Epidemiology and patterns of health care use. Neurology 2002;58:885-894.
7. Kruit MC, van Buchem MA, Hoffman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291:427-434.
8. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or burden of illness? Headache 2001;41:629-637.
9. Scher AI, Lipton RB, Stewart WF. Risk factors for chronic daily headache. Curr Pain Headache Rep 2002;6:486-491.
10. Aukerman G, Knutson D, Miser WF. Management of the acute migraine headache. Am Fam Physician 2002; 66:2123-2130.
11. Silberstein SD. Migraine: Preventive treatment. Cephalagia 2002;22:491-512.
12. Silberstein SD. Practice Parameter: Evidence-Based Guidelines for Migraine Headache (An Evidence-Based Review). Report for the Quality Standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology 2000;55:754-762.
13. Gray RN, Goslin RE, McCrory DC, et al. Evidence Report Drug Treatments for the Prevention of Migraine. Technical Review 2.3, February 1999. Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025. Available from the National Technical Information Service, Accession No. 127953.
14. Snow V, Weiss K, Wall EM, Mottur-Pilson C. For the American Academy of Family Physicians and the American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002;137:840-849.
15. Tfelt-Hansen P, Standnes B, Kangasneimi P, et al. Timolol vs. propranolol vs. placebo in common migraine prophylaxis: A double-blind multicenter trial. Acta Neurol Scand 1984;69:1-8.
16. Holroyd KA, Penzien DB, Coordingley GE. Propranolol in the management of recurrent migraine: A meta-analytic review. Headache 1991;31:333-340.
17. Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine: Effectiveness and relationship of antimigraine and antidepressant effects. Neurology 1976;26:121-127.
18. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-699.
19. Ziegler DK, Hurwitz A, Hassanein RS, et al. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987;44:486-489.
20. Markley HG, Cleronis JCD, Piepko RW. Verapamil prophylactic therapy of migraine. Neurology 1984;34:973-976.
21. Freitag FG, Diamond S, Diamond M, Urban G. Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41:271-278.
22. Klapper J and the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia 1997;17:103-108.
23. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-286.
24. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: An open-label long-term study (for the Long-Term Safety of Depakote in Headache Prophylaxis Study Group). Headache 1999;39:633-643.
25. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-128.
26. Mathew NT. Gabapentin in migraine prophylaxis. Cephalagia 1996;16:367.
27. Magnus-Miller L, Podolnick P, Mathew NT, Saper J. Efficacy and safety of gabapentin (Neurontin®) in migraine prophylaxis (Abstract No. 645). American Pain Society Program, 17th Annual Meeting, 1998.
28. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004;61:490-495.
29. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291:965-973.
30. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache 2002;42:85.
31. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1992;38:317-323.
32. Bailer M. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43:763-780.
33. Lipton RB, Gobel H, Wilks K, Mauskop A. Efficacy of Petasites (an extract from Petasites rhizome) 50 and 75 mg for prophylaxis of migraine: Results of a randomized, double-blind, placebo-controlled study (Abstract). Neurology 2002;58(Suppl 3):A472. Presented at the 44th American Headache Society Scientific Meeting, June 21-23, 2002, Seattle.
34. Grossman M, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Int J Clin Pharmacol Ther 2000;38:430-435.
35. Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache 2003;43:76-78.
36. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: Results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalagia 1996;16:257-263.
37. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: A double-blind, placebo-controlled study. Cephalagia 1996;16:436-440.
38. Schoenen J, Jacguy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology 1998;50:466-470.
39. Rozen T. Coenzyme Q10 in migraine. American Council on Headache Education, Summer 2003 newsletter.
40. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: A systematic review. Cephalagia 1998;18:704-708.